Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes
NCT ID: NCT00703599
Last Updated: 2008-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2007-11-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
This is the only arm and that is the treatment group.
Autologous Adipose-derived Stem cells
Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous Adipose-derived Stem cells
Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Insulin-dependent
Exclusion Criteria
16 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Adistem Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adistem Ltd
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emeritta A Barrenechea, MD
Role: PRINCIPAL_INVESTIGATOR
Veterens Memorial Medical Centre, Philippines
Florencio Q Lucero, MD
Role: PRINCIPAL_INVESTIGATOR
University of Philippines, College of Medicine
Letitia Lucero-Palma, MD
Role: STUDY_DIRECTOR
Far Eastern University-NRMF Hospital, Quezon City, Philippines
Bill Paspaliaris, PhD
Role: STUDY_CHAIR
Adistem Ltd, Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beverly Hills Medical Group
Makati City, Manila, Philippines
Veterens Memorial Medical Centre
Quezon City, Manila, Philippines
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Florencio Q Lucero, MD
Role: primary
Emerita A Barrenechea, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007 May 11;100(9):1249-60. doi: 10.1161/01.RES.0000265074.83288.09.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ad-003
Identifier Type: -
Identifier Source: org_study_id